ICOTF - iCo Therapeutics Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

iCo Therapeutics Inc.

777 Hornby Street
6th Floor
Vancouver, BC V6Z 1S4

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Andrew J. Rae M.B.A., BSc, MBACo-Founder, CEO, Pres & DirectorN/AN/A1967
Mr. Michael Liggett B.Sc., C.A., C.P.A., CPA, CA, Bsc. Pharm.CFO, Corp. Sec. & DirectorN/AN/A1960
Dr. Peter Hnik M.D., MHScChief Medical OfficerN/AN/A1956
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat sight threatening ocular allergies and various systemic disease indications; and Oral AmpB Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections. The company was founded in 2005 and is headquartered in Vancouver, Canada.

Corporate Governance

iCo Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.